We are live on ! Find out more
CARM

Carisma Therapeutics

Delisted

CARM was delisted on the 10th of October, 2025.

25 hedge funds and large institutions have $8.34M invested in Carisma Therapeutics in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

404% more capital invested

Capital invested by funds: $1.66M → $8.34M (+$6.68M)

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

9% more funds holding

Funds holding: 2325 (+2)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
25
Holders Change
+2
Holders Change %
+8.7%
% of All Funds
0.67%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
10
Increased
4
Reduced
4
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BIM
26
BlackRock Investment Management
Delaware
-$1K -90 Closed
Bank of America
27
Bank of America
North Carolina
+$51 +2 New
AG
28
Advisor Group
Arizona
+$329 +13 New
CG
29
Cutler Group
California
+$380 +15 New

CARM Hedge Fund Activity: Q2 2016 in Review

25 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2016, worth a combined $8.34M — up 404% from $1.66M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CARM positions and 6 closed out — a net gain of 4 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $1.27M. The largest seller was Sabby Management, exiting entirely with an estimated $387K sold.

  • 25 institutional investors held Carisma Therapeutics (CARM) as of Q2 2016, up from 23 in Q1 2016.
  • Funds reported $8.34M of Carisma Therapeutics stock for Q2 2016, up 404% quarter-over-quarter.
  • 10 funds opened new Carisma Therapeutics positions in Q2 2016 and 6 closed out, a net change of +4 holders.
  • The largest Carisma Therapeutics buyer in Q2 2016 was Boxer Capital, an estimated $1.27M added.
  • The largest Carisma Therapeutics seller in Q2 2016 was Sabby Management, an estimated $387K sold.

Based on aggregated 13F filings for Q2 2016.